Morphine / hydromorphone / oxycodone / heroin and tramadol

https://dxm-atlas.org/en/compare/morphine-vs-tramadol/

Two separate pairs are shown: DXM + A and DXM + B. Assessing DXM + A + B falls outside the scope of this comparison.

Comparison sections

Overlapping ranges: the ordering by hazard level remains uncertain

PHI and scope

A

Group assessment

This PHI covers the named group; its members do not have separate PHI ratings.

Conditions and group scope

A

Morphine, hydromorphone, oxycodone, heroin

B

Tramadol

Mechanisms

A

OP — μ-opioid effects · SED — Sedation

B

OP — μ-opioid effects · SERT — Serotonin reuptake · SEIZ — An additional seizure-related concern

What could go wrong?

A

The main concerns involve breathing, consciousness and material entering the airways. These opioids differ from tramadol in their effects on serotonin reuptake [5].

B

Serotonergic effects [5]; seizures and opioid effects [51]; multiple pathways of toxicity

How well is this understood?

A

Mechanism confidence: high

Confidence in the mechanism: high

M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.

Method
Confidence in human DXM data: low

Confidence in direct human evidence involving DXM: low

M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.

Method
differs

B

Mechanism confidence: high

Confidence in the mechanism: high

M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.

Method
Confidence in human DXM data: medium

Confidence in direct human evidence involving DXM: medium

M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.

Method
differs

Under which conditions was it studied?

A

Laboratory testing outside the body

B

Medicine prescribing information

Main limitations

This field lists specific limitations of the evidence described for each entry. “—” means no separate text is shown here; qualifications in the entry’s explanation still apply.

A

The result concerns SERT and NET inhibition under that laboratory assay’s conditions; effects in vivo may differ [5].

B

The scope is the opioid’s own pharmacology as described in its prescribing information.

Sources

Similarities and differences

Effects involved

Only A: SED — Sedation

Shared: OP — μ-opioid effects

Only B: SERT — Serotonin reuptake · SEIZ — An additional seizure-related concern

Mechanism groups

Shared: Sedation and respiration

Only B: Serotonin-related · Seizure-related concern

Potential problems

Only A: Aspiration

Only B: Seizures

Study conditions

Only A: Laboratory testing outside the body

Only B: Medicine prescribing information

Conclusion

Experiments with human transporters show substantial differences between opioids. Tramadol, pethidine, and methadone have serotonergic mechanisms, whereas morphine and hydromorphone did not demonstrate analogous SERT inhibition in the studied system. Fentanyl has a separate clinical serotonergic signal without the same transporter inhibition. Tapentadol inhibited SERT at potentially clinically relevant concentrations and was the most potent NET inhibitor among the tested opioids. The transporter mechanism is well supported; uncertainty concerns the clinical severity of the DXM pair, so its M confidence is High and D remains Low [5].

Limitations

With nonserotonergic opioids, the principal concerns are breathing and consciousness. The assessment rests on pharmacological mechanisms; the extent of their amplification with DXM remains uncertain. There is no basis for relying on DXM to protect against opioid toxicity.

Learn
Select entry
Reference

Open the source and related combinations →